Ability to Maintain Saturation Levels Without Oxygen Supplementation as a Extubation Criteria Without TOF Monitoring Equipment
Launched by UNIVERSITY OF SURABAYA · Feb 15, 2024
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The availability of Train-of-Four (TOF) monitoring devices is not yet widespread in some clinical practices. Practitioners are also often unaware of the high incidence of residual paralysis and the associated risks in their daily practice. However, residual paralysis increases the occurrence of airway obstruction, hypoxemia, and postoperative pulmonary complications. Therefore, clinical parameters for extubation criteria must ensure the absence of residual paralysis.
Administering oxygen in the ambient air can identify hypoventilation conditions. Therefore, patients who can maintain oxygen...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Elective surgery
- • 2. Adult patiens aged 18-60 years
- • 3. ASA physical status I-II
- • 4. Not receiving oxygen supplementation during pre-operative care
- Exclusion Criteria:
- • 1. History of hypersensitivy or allergy to neostigmine, muscular blockade agents, or anesthetic agents given
- • 2. Head or neck surgery
- • 3. Inability to access the ulnar nerve for TOF measurement device placement
- • 4. History of lung diseases such asthma, COPD, or pleural effusion
- • 5. Hepatic impairment with liver enzyme values \> 50% of the normal range
- • 6. Renal insufficiency (serum creatinine \> 1.8 mg/dl) or kidney failure
- • 7. Patients with neuromuscular diseases
- • 8. Body mass index (BMI) \> 35 kg/m2
- • 9. Consumption of medications that affect neuromuscular transmission such as aminoglycoside, polymyxin, lincomycin, clindamycin, and tetracycline; local anesthetic agent, procainamide, quinidine, lithium, magnesium sulfate, furosemide, cyclosporine, dantrolene, anti-estrogens, anticonvulsant, calcium, steroid, and azathioprine.
- • 10. Patients with contraindications to neostigmine or atropine sulfate
- • 11. Planned post-operative intensive care unit treatment
About University Of Surabaya
The University of Surabaya is a leading academic institution dedicated to advancing research and education in the health sciences. As a clinical trial sponsor, the university is committed to conducting innovative studies that contribute to the understanding and treatment of various medical conditions. With a focus on ethical standards and regulatory compliance, the University of Surabaya collaborates with healthcare professionals and researchers to ensure the integrity and validity of its clinical trials. Through its multidisciplinary approach, the university aims to enhance patient outcomes and foster advancements in medical knowledge, making significant contributions to both local and global health initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Yogyakarta, , Indonesia
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported